1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 382, NCT00691236
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 50
Sponsor: Pharmaceutical / Industry
Protocol IDs: TR02-2421, NCT00102531
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021020, NCT00560235
|
|
4.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 8 to 65
Sponsor: Other
Protocol IDs: 381, NCT00689195
|
|
5.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: SARC003, NCT00073983, NCI-04-C-0001, AEWS0421, MAYO-79-2003
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: Other
Protocol IDs: NAVE-CYCLO, NCT00180947
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 13
Sponsor: Other
Protocol IDs: SARC009, NCT00464620
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-07-C-0230, 07-C-0230, NCT00550654
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 11 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P04720, NCT00617890
|
|
15.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UMCC 2008.049, NCT00743509
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 74
Sponsor: Other
Protocol IDs: SARC012, D8180C00039, NCT00752206
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C24114, EUDRACT- Nr. 2007-005294-60, NCT00767819
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-1299, NCT00802880
|
|
19.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 30 years
Sponsor: NCI
Protocol IDs: COG-ADVL0821, ADVL0821, NCT00831844
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 2 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NO21157, SARC011, NCT00642941
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 70
Sponsor: Other
Protocol IDs: 0457-08-HMO-CTIL, NCT00855452
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 75
Sponsor: Other
Protocol IDs: HGosteo-BAY, EudraCT Number: 2007-004396-19, NCT00889057
|
|
23.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CCCWFU-71108, CCCWFU 71108, IRB00008212, NCT00974545
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: SIM-65, NCT01002092
|
|
25.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-09097, 09-097, 8121, NCT01016015
|
